10.03.19

Allergan to Showcase Late-Stage Data in AMD and Glaucoma at AAO Annual Meeting

Source: Allergan

Allergan will present new data from investigational abicipar and bimatoprost sustained release (SR) at the annual meeting of the American Academy of Ophthalmology (AAO) to be held in San Francisco, California. The Retina Subspecialty Day (October 11-12) will feature a late-breaker presentation on 2-year data from the CEDAR and SEQUOIA clinical studies of abicipar in patients with neovascular age-related macular degeneration (nAMD). Data will also be presented during a paper session on October 14for bimatoprost SR, which has the potential to be a first-in-class sustained-release, biodegradable implant for the reduction of IOP in patients with ocular hypertension or open-angle glaucoma, including topline results from two phase 3 studies in open-angle glaucoma and ocular hypertension. Additional company-sponsored data will also be presented at the meeting as ePosters.

“The data presented at AAO for our late stage, investigational assets, abicipar and bimatoprost sustained-release, showcase our continued commitment to innovation in ophthalmology,” Yehia Hashad, MD, Senior Vice President, Head of Global Clinical Development Allergan, said in a company new release. “We’re excited to share data that may redefine treatment approaches in neovascular age-related macular degeneration and glaucoma, and may improve upon the current state of patient care.”

Allergan will present four abstracts, including two oral presentations and two ePoster presentations (all noted in local Pacific Time):

Retina Subspecialty Day, Late Breaking – RET 11 – Section VIII: Late Breaking Developments, Part I (Friday, October 11, 4:18 – 4:58 PM):

  • Abicipar for Neovascular Age‐related Macular Degeneration: Two-Year Results from CEDAR and SEQUOIA Phase 3 Clinical Trials
    • Author: Khurana R.
    • Time: 4:34 – 4:39 PM

OP09 Glaucoma Original Papers Session (Monday, October 14, 2:00 – 5:15 PM):

  • Phase 3 Evaluation of Bimatoprost Sustained-Release Implant in Patients With Glaucoma or Ocular Hypertension: Results at Primary Database Lock
    • Authors: Craven ER et al.
    • Time: 2:12 – 2:24 PM

Retina ePoster Presentations:

  • Cumulative Retinal Fluid Exposure Reduces Visual Acuity Gain During Anti-VEGF Therapy. An Analysis of CATT 2-Year Data
    • Authors: Singer M et al.
  • Early vs Late Switch to Dexamethasone Intravitreal Implant in Anti-VEGF Nonresponders with Diabetic Macular Edema in the AUSSIEDEX Study
    • Authors: Mitchell P et al.

 

Related Content